Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
25°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Latest News about treatment/resistant depression
Recent news which mentions treatment/resistant depression
Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant
August 14, 2024
Tickers
ATAI
Tags
ATAI
DMT/Assisted Therapy
Benzinga
From
Benzinga
Pharma Giant Johnson & Johnson Asks FDA To Approve Esketamine Nasal Spray For Treatment-Resistant Depression
July 23, 2024
Tickers
JNJ
NEWS
Tags
eketamine nasal spray
ketamine depression
JNJ
From
Benzinga
First Patient Dosed In Psychedelics Therapy Study For Treatment-Resistant Depression
April 26, 2024
Tickers
NEWS
Tags
Cannabis
BPL/003
treatment/resistant depression
From
Benzinga
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression
March 28, 2024
Tickers
ATAI
NEWS
Tags
treatment/resistant depression
Cannabis
Market News
From
Benzinga
Compass Pathways Shows Robust 2023 Year-End Results, Embraces Clinical Milestones For Psilocybin As Depression Treatment
February 29, 2024
Tickers
CMPS
Tags
Benzinga
psilocybin therapies
Psychedelic/Assisted Therapies
From
Benzinga
UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center
November 15, 2023
Tickers
AWKNF
CMPS
Tags
Psilocybin program
Ketamine/Assisted Therapy
Markets
From
Benzinga
Atai Life Sciences Completes Phase 1 Clinical Study Of Oral Film DMT Formulation
October 03, 2023
Tickers
ATAI
Tags
News
Market News
DMT Clinical Trial
From
Benzinga
Compass Pathways Explores AI-Powered Predictive Model On Psilocybin Therapy For Depression
September 06, 2023
Tickers
CMPS
Tags
Psilocybin program
Management
Markets
From
Benzinga
GH Research Psychedelics Firm Q2 2023 Reports $238M Cash To Accelerate 5-MeO-DMT Programs Into 2026
August 24, 2023
Tickers
GHRS
Tags
Small Cap
News
Guidance
From
Benzinga
Compatibility Of Psilocybin & SSRIs For Depression, COMPASS Looks At 'Psychedelic-Assisted Therapies'
July 18, 2023
Tickers
CMPS
Tags
Psilocybin program
Psychedelic/Assisted Therapies
Psychedelics
From
Benzinga
COMPASS Pathways Secures Up To $50M In Term Loan Facility With Hercules Capital
July 05, 2023
Tickers
ATAI
CMPS
HTGC
Tags
News
Small Cap
treatment/resistant depression
From
Benzinga
Numinus' Clinical Site Joins Compass' Phase 3 Program On Psilocybin Therapy For TRD
May 30, 2023
Tickers
CMPS
NUMIF
Tags
Small Cap
News
NUMIF
From
Benzinga
GH Research: Q1 2023 Financials And Businesses For European 5-MeO-DMT Depression Treatment Developer
May 11, 2023
Tickers
GHRS
Tags
Biotech
Earnings
Psychedelics
From
Benzinga
Beckley Psytech Begins Phase IIa Study Of Psychedelic Compound To Treat Depression
May 04, 2023
Tags
Market News
Benzinga
Markets
From
Benzinga
Cathie Wood Reacts To Atai's Drastic Stock Plunge After Doomed Clinical Study Results
January 12, 2023
Tickers
ATAI
CMPS
IGXT
Tags
Cathy Wood
Small Cap
News
From
Benzinga
Magic Mushrooms Tested For Treating Type II Bipolar Disorder, Check Out Results So Far
December 12, 2022
Tickers
CMPS
Tags
Cannabis
treatment/resistant depression
psilocybin therapy
From
Benzinga
Psychedelics And Treatment-Resistant Depression: COMPASS Pathways Replies To Comments
December 09, 2022
Tickers
CMPS
Tags
Legal
Guidance
Small Cap
From
Benzinga
Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS' Latest Trial Outcomes
November 16, 2022
Tickers
CMPS
Tags
Small Cap
News
Psilocybin
From
Benzinga
Psychedelics Company's $60M Series A For Startup To Develop Treatment For Mental Health Disorders
November 02, 2022
Tags
Lusaris Therapeutics
Contracts
Benzinga
From
Benzinga
atai's Phase 1 Synthetic DMT-Based Drug Clinical Trial Begins Patient Dosing
October 05, 2022
Tickers
ATAI
Tags
Small Cap
News
Cannabis
From
Benzinga
Psilocybin For Anorexia: Learn About Compass' Novel Phase 2 Trial Using Magic Mushroom's Main Compound
July 28, 2022
Tickers
CMPS
Tags
Anorexia Nervosa
Small Cap
News
From
Benzinga
Psilocybin More Effective Than Antidepressants In Treating Depression, New Study Shows
April 12, 2022
Tags
Market News
treatment/resistant depression
Cannabis
From
Benzinga
COMPASS Pathways: Positive Psilocybin Trial, High-Dose Group Improves Beyond Depression Reduction
December 01, 2021
Tickers
CMPS
Tags
Biotech
Positive and Negative Affect Schedule
Markets
From
Benzinga
Mike Tyson: How A Drug Derived From Toad Venom Made Him Comfortable With Dying
November 16, 2021
Tickers
GHRS
Tags
Sonoran desert toad
Topics
Health Care
From
Benzinga
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.